Clinical Trials

42 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT06863311 2026-03-16

EXACT

70 enrolled

Carcinoma, Renal Cell

NCT05098210 2026-03-12

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

25 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06053658 2026-03-11

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

48 enrolled

Carcinoma, Renal Cell

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

14 enrolled

Prostatic Neoplasms

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

36 enrolled

Melanoma

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Gastroesophageal Adenocarcinoma

NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

54 enrolled

Lymphoid

Hodgkin Disease

NCT04380545 2026-03-06

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

15 enrolled

Carcinoma, Hepatocellular

NCT03026140 2026-03-05

NICHE

353 enrolled

Colonic Neoplasms

NCT05677490 2026-03-04

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

382 enrolled

Adenocarcinoma Of Esophagus

NCT06523621 2026-03-04

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Plasma cell

Multiple Myeloma

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Phase EARLY_PHASE1 Recruiting

Lung Neoplasms

NCT04741997 2026-03-02

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma

NCT05048212 2026-03-02

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT06346197 2026-03-02

CIME

132 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT07281924 2026-03-02

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

15 enrolled

Melanoma

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

33 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07188896 2026-02-23

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

120 enrolled

Carcinoma, Renal Cell

NCT07422779 2026-02-20

MAK

Phase NA Recruiting

100 enrolled

Melanoma, Skin Neoplasms

NCT06999980 2026-02-19

Neo IRENIE

494 enrolled

Melanoma

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Head & Neck

Thyroid Neoplasms

NCT05715229 2026-02-18

G360-IIT

108 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Carcinoma, Merkel Cell

NCT06963905 2026-02-17

SIMONE

60 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07230613 2026-02-11

NEOREM-NEO-1

Melanoma

NCT07398937 2026-02-10

ECTOP-1036

116 enrolled

Lung Neoplasms

NCT06534190 2026-02-09

CD8 PET Imaging in Metastatic Solid Tumours

Other solid neoplasm

Locally Advanced Solid Tumor

NCT05234307 2026-02-06

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07394062 2026-02-06

ALCG-01

Recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03465592 2026-02-05

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

39 enrolled

Sarcoma

NCT06624475 2026-02-05

NEON

Carcinoma, Basal Cell

NCT03340129 2026-02-02

ABC-X

218 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04562129 2026-01-29

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

29 enrolled

Melanoma, Skin Neoplasms

NCT06365619 2026-01-29

NeoRelapse

25 enrolled

Melanoma

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

60 enrolled

Prostatic Neoplasms

NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT05502315 2026-01-23

CANOPY

47 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02813135 2026-01-16

ESMART

472 enrolled

Tumor-Agnostic

Neoplasms

NCT05327686 2026-01-14

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT05704647 2026-01-14

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Melanoma

NCT05317000 2026-01-12

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06295159 2026-01-08

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

90 enrolled

Melanoma

NCT06968988 2026-01-08

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

18 enrolled

Sarcoma

NCT05779423 2026-01-06

Cryoablation+Ipilimumab+Nivolumab in Melanoma

37 enrolled

Melanoma, Skin Neoplasms

NCT05428007 2026-01-05

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

105 enrolled

Melanoma

NCT04933903 2025-12-30

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03803553 2025-12-23

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

400 enrolled